Abstract
TNF-related apoptosis inducing ligand (TRAIL) is a key mediator of the innate immune response to infection. While TRAIL-mediated apoptosis plays an essential role in the clearance of virus-infected cells, its physiologic role also includes immunosurveilance for cancer cells. Therapeutics that induce TRAIL-mediated apoptosis in cancer cells remain a focus of ongoing investigation in clinical trials, and much has been learned from these studies regarding the efficacy and toxicity of these interventions. These data, combined with data from numerous preclinical studies that detail the important and multifaceted role of TRAIL during infection with human immunodeficiency virus and other viruses, suggest that therapeutic exploitation of TRAIL signaling offers a novel and efficacious strategy for the management of infectious diseases.
Keywords: Infectious Diseases, TNF, apoptosis, ligand (TRAIL), cancer cells
Anti-Infective Agents in Medicinal Chemistry
Title: The Biology of TRAIL and the Role of TRAIL-Based Therapeutics in Infectious Diseases
Volume: 8 Issue: 2
Author(s): Brett D. Shepard and Andrew D. Badley
Affiliation:
Keywords: Infectious Diseases, TNF, apoptosis, ligand (TRAIL), cancer cells
Abstract: TNF-related apoptosis inducing ligand (TRAIL) is a key mediator of the innate immune response to infection. While TRAIL-mediated apoptosis plays an essential role in the clearance of virus-infected cells, its physiologic role also includes immunosurveilance for cancer cells. Therapeutics that induce TRAIL-mediated apoptosis in cancer cells remain a focus of ongoing investigation in clinical trials, and much has been learned from these studies regarding the efficacy and toxicity of these interventions. These data, combined with data from numerous preclinical studies that detail the important and multifaceted role of TRAIL during infection with human immunodeficiency virus and other viruses, suggest that therapeutic exploitation of TRAIL signaling offers a novel and efficacious strategy for the management of infectious diseases.
Export Options
About this article
Cite this article as:
Shepard D. Brett and Badley D. Andrew, The Biology of TRAIL and the Role of TRAIL-Based Therapeutics in Infectious Diseases, Anti-Infective Agents in Medicinal Chemistry 2009; 8 (2) . https://dx.doi.org/10.2174/187152109787846060
DOI https://dx.doi.org/10.2174/187152109787846060 |
Print ISSN 1871-5214 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6018 |
Related Articles
-
Mechanotransductive Receptor Piezo1 as a Promising Target in the
Treatment of Neurological Diseases
Current Neuropharmacology Mesenchymal Stem Cells Mediated Drug Delivery in Tumor-Targeted Therapy
Current Drug Delivery Isolation, Characterization and Preliminary Cytotoxic and Antifungal Evaluations of Novel Lancifoliate Isolated from Methanol Extract of <i>Conocarpus lancifolius</i>
Anti-Cancer Agents in Medicinal Chemistry Matrine-Family Alkaloids: Versatile Precursors for Bioactive Modifications
Medicinal Chemistry Current Status and Perspectives in the Development of Camptothecins
Current Pharmaceutical Design The ‘Other’ Telomerase Inhibitors: Non-G-Quadruplex Interactive Agent, Non-Antisense, Non-Reverse Transcriptase Telomerase Inhibitors
Current Medicinal Chemistry - Anti-Cancer Agents Antagonists of Growth Hormone-Releasing Hormone in Oncology
Combinatorial Chemistry & High Throughput Screening Targeting the Epidermal Growth Factor Receptor in Glioblastoma Treatment
Current Signal Transduction Therapy Cell Surface Nucleolin as a Target for Anti-Cancer Therapies
Recent Patents on Anti-Cancer Drug Discovery Structure and Ligand Based Drug Design Strategies in the Development of Novel 5- LOX Inhibitors
Current Medicinal Chemistry Synergistic Interplay of Medicinal Chemistry and Formulation Strategies in Nanotechnology – From Drug Discovery to Nanocarrier Design and Development
Current Topics in Medicinal Chemistry The Renin-angiotensin System as a Target of Novel Anticancer Therapy
Current Pharmaceutical Design Targeting SphK1 as a New Strategy against Cancer
Current Drug Targets New Gene Therapy Strategies for Cancer Treatment: A Review of Recent Patents
Recent Patents on Anti-Cancer Drug Discovery Anti-tumor Effects of Curcuminoids in Glioblastoma Multiforme: An Updated Literature Review
Current Medicinal Chemistry The Role of Cetuximab and Other Epidermal Growth Factor Receptor Monoclonal Antibodies in the Treatment of Advanced Non-Small Cell Lung Cancer
Reviews on Recent Clinical Trials Targeting Nodal and Cripto-1: Perspectives Inside Dual Potential Theranostic Cancer Biomarkers
Current Medicinal Chemistry EDITORIAL [Hot topic: New Therapeutic Advances and Perspectives in Tumour Angiogenesis (Guest Editor: Eddy Pasquier)]
Current Cancer Drug Targets Nanomedicine Strategies for Sustained, Controlled and Targeted Treatment of Alzheimer’s Disease
Mini-Reviews in Medicinal Chemistry Recent Advances on Radionuclide Labeled Hypoxia-Imaging Agents
Current Pharmaceutical Design